Pacira Pharmaceuticals diskutieren
Pacira Pharmaceuticals
WKN: A1H68T / Symbol: PCRX / Name: Pacira Pharma / Aktie / Pharmazeutika / Small Cap /
12,30 €
-
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $57.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $43.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $42.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Truist Financial Co. from $45.00 to $30.00. They now have a "buy" rating on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $43.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Royal Bank of Canada from $42.00 to $37.00. They now have an "outperform" rating on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Raymond James from $41.00 to $37.00. They now have an "outperform" rating on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "underweight" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $10.00 price target on the stock, down previously from $45.00.
Ratings data for PCRX provided by MarketBeat
Neueste Beiträge
StockNews_com in Concord Medical Serv. ADR diskutieren